Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02296541 · ClinicalTrials.gov registry record · Phase 1
Evaluating the Safety and Immune Response to Three Different DNA HIV Vaccines Administered With a MVA-CMDR Boost Vaccine in Healthy, HIV-Uninfected Adults
A Phase 1 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 105
- Enrollment target
NCT02296541 is a Phase 1 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 105 participants.
The verdict
NCT02296541, a Phase 1 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 105 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and immune response to three DNA vaccines and a MVA-CMDR vaccine that may boost the immune response to the DNA vaccines in healthy, HIV-uninfected adults.
Interventions
- BIOLOGICAL MVA-CMDR
- BIOLOGICAL DNA Nat-B env
- BIOLOGICAL DNA CON-S env
- BIOLOGICAL DNA Mosaic env
- BIOLOGICAL Placebo for DNA Nat-B env
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 2014-12 |
| Est. Completion | 2020-07-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02296541
The ClinicalTrials.gov registry entry for NCT02296541 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 105 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which MVA-CMDR is the first listed.
NCT02296541 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02296541 about?
NCT02296541 is a clinical study titled "Evaluating the Safety and Immune Response to Three Different DNA HIV Vaccines Administered With a MVA-CMDR Boost Vaccine in Healthy, HIV-Uninfected Adults". The purpose of this study is to evaluate the safety and immune response to three DNA vaccines and a MVA-CMDR vaccine that may boost the immune response to the DNA vaccines in healthy, HIV-uninfected adults.
What is the current status of trial NCT02296541?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 105 participants. The study started on 2014-12. Estimated completion is 2020-07-06.
What interventions are being tested in trial NCT02296541?
The interventions under investigation include: MVA-CMDR (BIOLOGICAL), DNA Nat-B env (BIOLOGICAL), DNA CON-S env (BIOLOGICAL), DNA Mosaic env (BIOLOGICAL), Placebo for DNA Nat-B env (BIOLOGICAL).
Who is sponsoring clinical trial NCT02296541?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.